State coverage
Minnesota Medicaid and GLP-1 coverage
Medicaid, for obesity: Covers for weight loss. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Covers Saxenda, Wegovy and Zepbound with prior authorization. Renewal needs 5% weight loss.
- Appeal deadline
- 30 days from the day you received the notice, or up to 90 days if the state accepts good cause source
- Date read
- September 2026
Minnesota names the drugs it will pay for and publishes the criteria as a plain web page rather than burying them in a form, which makes it one of the easier states to read. The answer is yes with conditions, and the conditions are unusually specific about what happens after the first prescription.
Two features stand out. The first is that continuing is a test rather than a formality: the state asks for a measured result during the initial approval period, and it asks again, differently, once you pass eighteen months. The second is that the drugs are split across two criteria pages depending on why they are being prescribed, and the page you need is decided by the reason rather than the drug.
That second point catches people. If the request is for weight loss, one page governs. If it is for a cardiovascular, liver or sleep-apnea indication, a different page governs, and each of those routes asks for a named specialist to be involved. The same drug, two rulebooks, and the deciding factor is the diagnosis on the request.
There is no drug-list finding for Minnesota here. The state serves its list from a link that hands back a much older edition — the header still reads July 1, 2019 — so there is no address that reliably points at the current one. Nothing on this page rests on that document.
What we could verify for Minnesota
Minnesota names the anti-obesity drugs it covers and requires approval for all of them. Its criteria page, headed "Drug - Anti-Obesity Medications" and dated August 2026, lists as "Covered drugs with prior authorization": benzphetamine, Contrave, diethylpropion, Lomaira, orlistat, phendimetrazine, phentermine capsules and tablets, Saxenda, Wegovy, Xenical and Zepbound.
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
The entry test is a body mass index floor with a comorbidity alternative, and it is age-banded. The criteria require a baseline BMI "Greater than or equal to 30 kg/m2 with no risk factors (for patient at least 18 years of age)" or "Greater than or equal to 27 kg/m2 with at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) (for patient at least 18 years of age)" or "Greater than or equal to 30 kg/m2 and body weight above 60 kg (for patient 12 to 17 years of age)." The state also asks that "Patient's weight at baseline (in kg) must be submitted at time of request," and requires documented diet or dietitian care plus increased physical activity unless a comorbidity makes it inadvisable. There must be "No concurrent use of any other weight loss drug(s)."
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
How long a first approval lasts depends on which drug it is, and one group cannot be renewed at all. The criteria give "6 months for Saxenda, Wegovy, Contrave, Xenical or orlistat; and may be renewed if renewal criteria is met," against "3 months for phentermine tablets and capsules, Lomaira, benzphetamine, diethylpropion or diethylpropion ER, phendimetrazine or phendimetrazine ER; and cannot be renewed." For both groups the page adds that after a lapse in therapy, "additional trials may be approved if initial approval criteria is met."
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
Continuing turns on a measured result, and the measure changes with age. To renew, a patient "at least 18 years of age, must have at least 5% weight loss during the initial approval period," or a patient "12 to 17 years of age, must have at least 5% reduction in baseline BMI during the initial approval period," alongside ongoing diet or dietitian care and ongoing physical activity. A renewal runs 12 months. There is a second, different test further out: "Subsequent renewal approval (beyond 18 months) requires meeting all renewal criteria and documentation that patient maintains weight loss achieved during the initial approval period."
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
Which criteria page applies is decided by the reason for the prescription, not by the drug. Minnesota's Weight Management Agents page states that "All drugs require prior authorization," and then splits: for drugs "being requested for weight loss purposes, coverage may be provided if members meet the prior authorization (PA) criteria for 'Anti-Obesity Medications'," while "For agents with other FDA-approved indications that are not being requested for weight loss purposes," the criteria on that page govern instead.
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
Each non-weight-loss route asks for a named specialist to be involved. The cardiovascular pathway requires a "Diagnosis of established cardiovascular (CV) disease," documented management of CV risk factors, and that the "Requested agent is prescribed by or in consultation with a cardiologist." The liver pathway requires noncirrhotic MASH with "Moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)" and consultation with "a gastroenterologist or hepatologist." All routes require no concurrent use of another GLP-1 receptor agonist, and initial and renewal approval run up to 12 months.
Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 · source
Minnesota's appeal window is 30 days and it runs from receipt, with a longer route for good cause. The statute provides that an individual "may contest the specified action, decision, or final disposition before the state agency by submitting a written request for a hearing to the state agency within 30 days after receiving written notice of the action, decision, or final disposition, or within 90 days of such written notice if the applicant, recipient, patient, or relative shows good cause, as defined in section 256.0451, subdivision 13, why the request was not submitted within the 30-day time limit." The same section opens by deferring to any different time frame set by federal or Minnesota law.
Minnesota Statutes §256.045, subdivision 3, Office of the Revisor of Statutes · source
Minnesota is one of 10 states whose Medicaid gives the same answer: pay for these drugs for weight loss, with prior authorization. Minnesota Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Minnesota with the rest in the coverage matrix.
If you work for the State of Minnesota
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: Minnesota Advantage Health Plan (SEGIP). Its pharmacy benefit runs through CVS Caremark.
Covered with PA tied to a weight program
Minnesota's Advantage plan excludes weight-loss drugs unless they're medically necessary and part of a plan-approved program. Caremark's 2025 prior authorization report for the plan shows Wegovy requests that met plan criteria, and others denied for having no comprehensive weight management program.
The plan excludes "charges for weight loss, drugs, and programs, including program fees or dues, nutritional supplements, food, appetite suppressants, vitamins, and exercise therapy unless Medically Necessary, appropriate Treatment, and a Plan-approved program".
Minnesota Management and Budget, SEGIP, Summary of Benefits 2026, Minnesota Advantage Health Plan, effective January 2026 · source
"CVS Caremark is the Pharmacy Benefit Manager for the Advantage Plan regardless of the Health Plan Administrator you select."
Minnesota Management and Budget, SEGIP, Summary of Benefits 2026, Minnesota Advantage Health Plan, effective January 2026 · source
In Caremark's 2025 prior-authorization report for the state plan, Wegovy requests were approved as "Met Plan Criteria" and others were denied for "No comprehensive weight management program".
CVS Caremark, SEGIP MN Pharmacy Prior Authorization Regulatory Reporting for State of MN, 2025, effective December 2025 · source
"The Advantage Plan may cover a weight loss program if it is Medically Necessary, appropriate Treatment and Plan-approved."
Minnesota Management and Budget, SEGIP, Summary of Benefits 2026, Minnesota Advantage Health Plan, effective January 2026 · source
If the appeal fails, or you cannot wait
Minnesota Medicaid pays for these drugs for weight loss with prior authorization, so a denial there is worth appealing before anything else. If the appeal fails, or you can't wait for it, cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerSprout HealthCheck availability | Compounded semaglutide from $149 a month and tirzepatide from $199, on plans that renew automatically. Also lists brand Wegovy and Zepbound. |
| PartnerWillowCheck availability | Compounded semaglutide at $299 a month (weekly injection or daily tablet) and tirzepatide injections at $399. HSA and FSA accepted; a full refund applies only if you cancel before the prescription reaches the pharmacy. |
| PartnerHumeCare+Check availability | A self-pay membership with no price shown before checkout, renewing automatically. The home page promises your money back if you don't lose 10 percent in six months; the terms limit that to 90 days, first-time users and no measurable loss. |
| PartnerEnhance MDCheck availability | Offers compounded semaglutide and tirzepatide with provider consultations and follow-up. Compounded drugs are not FDA-approved; ask which pharmacy will dispense your prescription and what continuing care includes. |
| PartnerCoreAge RxCheck availability | Compounded semaglutide advertised at $99 a month at every dose. The page our link opens has shown $149 instead, and a consultation fee can be added that may not be refundable. |
| PartnerOakCheck availability | One flat price at every dose, with shipping and supplies included free. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, October 2026 and August 2026, and they change often. Check the current number before you buy.
Where this comes from
- Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 — mn.gov/dhs/partners-and-providers/policies-procedures/minnesota-health-c
- Minnesota Department of Human Services, Minnesota Health Care Programs, effective August 2026 — mn.gov/dhs/partners-and-providers/policies-procedures/minnesota-health-c
- Minnesota Statutes §256.045, subdivision 3, Office of the Revisor of Statutes — www.revisor.mn.gov/statutes/cite/256.045